NEW YORK (GenomeWeb) – Oncology diagnostics firm Cancer Genetics today announced that its CLIA-certified, CAP-accredited laboratory has received the California Clinical Laboratory License, which will allow the company to perform its oncology testing services on patient samples from the state of California.
The Rutherford, NJ-based firm said in a statement that it believes its proprietary tests for non-Hodgkin's lymphoma (NHL) and leukemia will be of particular benefit to the state, where more than 6,800 new patients are diagnosed with NHL, and 4,300 patients are diagnosed with leukemia each year.
"Approval to provide our comprehensive oncology tests and services throughout California opens up the single largest US oncology diagnostics market to CGI, and will help accelerate our commercial growth," Cancer Genetics CEO Panna Sharma said in a statement.
Cancer Genetics received CLIA and New York State approvals in May 2014 to offer its lymphoma tests and got the same approvals for its leukemia tests in February 2013.